Your browser doesn't support javascript.
loading
Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease.
Khine, Annika; Kwok, Jonas; Lin, Eugene.
Afiliação
  • Khine A; Department of Medicine, Division of Nephrology, Keck School of Medicine of the University of Southern California, Los Angeles, California.
  • Kwok J; Department of Medicine, Los Angeles County+USC Medical Center, Los Angeles, California.
  • Lin E; Department of Medicine, Division of Nephrology, Keck School of Medicine of the University of Southern California, Los Angeles, California; The Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California; Sol Price School of Public Policy, University of Southern California, Los Angeles, California. Electronic address: eugeneli@usc.edu.
Am J Kidney Dis ; 79(6): 780-782, 2022 06.
Article em En | MEDLINE | ID: mdl-35115191
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: Am J Kidney Dis Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: Am J Kidney Dis Ano de publicação: 2022 Tipo de documento: Article